

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



TAF II p135/p105 (E977) Peptide

Cat No.: BS2239P

Background

TAF II p105, also called TAF4B, is a celltype specific transcriptional co-activator that is a component of the TFIID complex. Expressed primarily in B cells and ovarian granulosa cells, TAF II p105 can interact with OCBA/POU2AF1 to activate B cell-specific octamerdependent transcription. Additionally, TAF II p105 plays an important role in co-activating the transcription factor NFκB and is essential for activation of anti-apoptotic genes such as TNFAIP3. TAF II p135, also known as TAF4, TAF2C, TAF2C1, TAF4A or TAFII130, is a 1,085 amino acid subunit of TFIID that accelerates transcriptional activation triggered by thyroid hormone (TR) or retinoic acid (RA). Localized to the nucleus, TAF II p135 contains one TAFH domain and is thought to bind to proteins that contain glutamine-rich domains, such as the transcription factor CREB.

Swiss-Prot

O00268/Q92750

Applications

Blocking

Specificity

This peptide can be used with studies using BS2239 TAF II p135/p105 (E977) pAb.

Purification & Purity

Synthetic peptide TAF II p135/p105 (E977). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.